OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. Show more
Location: 6707 Winchester Circle, Boulder, CO, 80301, United States | Website: https://onkuretherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
32.42M
52 Wk Range
$1.70 - $20.00
Previous Close
$2.40
Open
$2.42
Volume
24,786
Day Range
$2.38 - $2.44
Enterprise Value
-63.28M
Cash
96.66M
Avg Qtr Burn
-13.62M
Insider Ownership
1.57%
Institutional Own.
98.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OKI-219 +/- Fulvestrant or Trastuzumab Details Breast cancer, Cancer | Phase 1 Data readout | |
Mavodelpar (REN001) Details long-chain fatty acid oxidation disorders | Failed Discontinued | |
Mavodelpar (REN001) Details primary mitochondrial myopathies | Failed Discontinued | |
Failed Discontinued |